149 related articles for article (PubMed ID: 10738240)
1. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma.
Ge K; Minhas F; Duhadaway J; Mao NC; Wilson D; Buccafusca R; Sakamuro D; Nelson P; Malkowicz SB; Tomaszewski J; Prendergast GC
Int J Cancer; 2000 Apr; 86(2):155-61. PubMed ID: 10738240
[TBL] [Abstract][Full Text] [Related]
2. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity.
Ge K; Duhadaway J; Sakamuro D; Wechsler-Reya R; Reynolds C; Prendergast GC
Int J Cancer; 2000 Feb; 85(3):376-83. PubMed ID: 10652430
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the expression of Bin1, a putative suppressor, in human hepatoma cells.
Livezey KW; Negorev D; Simon D
Cancer Genet Cytogenet; 2000 Jan; 116(1):35-9. PubMed ID: 10616529
[TBL] [Abstract][Full Text] [Related]
4. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma.
Ge K; DuHadaway J; Du W; Herlyn M; Rodeck U; Prendergast GC
Proc Natl Acad Sci U S A; 1999 Aug; 96(17):9689-94. PubMed ID: 10449755
[TBL] [Abstract][Full Text] [Related]
5. The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program.
Elliott K; Ge K; Du W; Prendergast GC
Oncogene; 2000 Sep; 19(41):4669-84. PubMed ID: 11032017
[TBL] [Abstract][Full Text] [Related]
6. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
7. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor.
Sakamuro D; Elliott KJ; Wechsler-Reya R; Prendergast GC
Nat Genet; 1996 Sep; 14(1):69-77. PubMed ID: 8782822
[TBL] [Abstract][Full Text] [Related]
8. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing.
Wechsler-Reya R; Sakamuro D; Zhang J; Duhadaway J; Prendergast GC
J Biol Chem; 1997 Dec; 272(50):31453-8. PubMed ID: 9395479
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
10. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells.
Kennah E; Ringrose A; Zhou LL; Esmailzadeh S; Qian H; Su MW; Zhou Y; Jiang X
Blood; 2009 May; 113(19):4646-55. PubMed ID: 19211505
[TBL] [Abstract][Full Text] [Related]
11. Bin1 mediates apoptosis by c-Myc in transformed primary cells.
DuHadaway JB; Sakamuro D; Ewert DL; Prendergast GC
Cancer Res; 2001 Apr; 61(7):3151-6. PubMed ID: 11306501
[TBL] [Abstract][Full Text] [Related]
12. Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition.
Wang X; Wang J; Jia Y; Wang Y; Han X; Duan Y; Lv W; Ma M; Liu L
Oncotarget; 2017 Mar; 8(12):19661-19673. PubMed ID: 28152502
[TBL] [Abstract][Full Text] [Related]
13. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
14. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
15. A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants.
Pineda-Lucena A; Ho CS; Mao DY; Sheng Y; Laister RC; Muhandiram R; Lu Y; Seet BT; Katz S; Szyperski T; Penn LZ; Arrowsmith CH
J Mol Biol; 2005 Aug; 351(1):182-94. PubMed ID: 15992821
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer.
Lehrer S; Rheinstein PH
Am J Clin Oncol; 2020 Oct; 43(10):685-689. PubMed ID: 32568785
[TBL] [Abstract][Full Text] [Related]
17. Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer.
Lehrer S; Rheinstein PH
Cancer Genomics Proteomics; 2020; 17(3):271-275. PubMed ID: 32345668
[TBL] [Abstract][Full Text] [Related]
18. Bau, a splice form of Neurabin-I that interacts with the tumor suppressor Bin1, inhibits malignant cell transformation.
Duhadaway J; Rowe F; Elliott K; Mao NC; Prendergast GC
Cell Adhes Commun; 1999; 7(2):99-110. PubMed ID: 10427963
[TBL] [Abstract][Full Text] [Related]
19. [Loss of heterozygosity of tumor suppressor genes at chromosome 3p in transitional cell carcinoma of urinary bladder].
Xiao Z; Zhang J; Zheng S; Li C; He Z; Cheng S; Gao Y
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(20):1375-7. PubMed ID: 12509916
[TBL] [Abstract][Full Text] [Related]
20. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene.
Chêne L; Giroud C; Desgrandchamps F; Boccon-Gibod L; Cussenot O; Berthon P; Latil A
Int J Cancer; 2004 Sep; 111(5):798-804. PubMed ID: 15252854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
